ETNB 89bio Corp Return on Sales by Gross Profit

Official company branding of 89bio Inc (ETNB)

89bio, Inc. (ETNB) is developing a therapy for the treatment of NASH, targeting the multi-billion dollar hepatology market. The gross profit margin demonstrates effective cost management, and its current value is 0.00. High investor confidence is bolstered by the company's scientific achievements in combating metabolic dysfunction. However, geopolitical instability and sanctions could slow drug synthesis and disrupt clinical trial timelines.

89bio (ETNB): Gross Profit Rate from 07/04/2022 to 11/15/2025

Financial and market metric breakdowns for 89bio.com (ETNB)

- current quotes and average value forecast:
Basic company analysis:ETNB 89bio Corp
Finished products of 89bio, Inc.

Gross margin measures the portion of revenue remaining after covering direct production costs, allowing for an assessment of the fundamental efficiency of profit generation per unit of product. By analyzing the gross margin ratio, an investor can discern the pricing power potential of 89bio, Inc., driven by the uniqueness of its liver fibrosis therapy and the lack of available alternatives, which renders demand inelastic and guarantees high sales profitability.